Leerink Partners Remains Bullish Following ARIAD Pharma's (ARIA) ESMO Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/17/2024
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
ARIAD Presents Updated Long-Term Follow-up Results from the Phase 1/2 Trial on Investigational Drug Brigatinib at 2016 ESMO Meeting
October 10, 2016 7:35 AM EDT~In ALK+ NSCLC patients with prior crizotinib treatment, the confirmed ORR was 62% and median PFS was 12.9 months
~In eight crizotinib-naive ALK+ NSCLC patients, the confirmed ORR was 100%
~Safety profile was similar with longer follow-up
CAMBRIDGE, Mass. & COPENHAGEN--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its... More
